Ligand-targeted therapeutics are a rapidly growing class of anticancer agents. This class of therapeutics is typically bifunctional molecules that use a targeting moiety to selectively deliver potent, typically nonspecific, cytotoxic agents to cancer cells while sparing normal cells. The low-molecular-weight of ligant-targeted therapeutics allows for better tumor penetration, especially in the case of solid tumors where the size of antibodies is a limiting factor for effective treatment. Unfortunately, the poor pharmacokinetic profiles of many of these conjugates present a challenge, which limits their tremendous therapeutic potential. Dose-limiting toxicity is also observed due to the need for high doses and frequent administration. This dissertation describes our work to develop a fundamentally new approach for targeting cancer. Our approach could potentially reduce the toxicity and enhance the pharmacokinetic properties of targeted anticancer agents, which would decrease dosing frequency and improve the lives of cancer patients.
| Identifer | oai:union.ndltd.org:pacific.edu/oai:scholarlycommons.pacific.edu:uop_etds-5020 |
| Date | 01 January 2017 |
| Creators | Albusairi, Wabel |
| Publisher | Scholarly Commons |
| Source Sets | University of the Pacific |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | University of the Pacific Theses and Dissertations |
Page generated in 0.0021 seconds